• Home
  • About IBT
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
    • Sustainability Policy
  • Pipeline
    • IBP-9414
    • IBP-1016
    • IBP-1118
    • IBP-1122
    • Expanded Access Policy for Investigational Drugs
  • Healthcare Professionals
  • Investors & Media
    • Shares
    • Share Issue
    • Ownership Structure
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • Investors & Media Contact
  • Contact Us
  • Career
IBT Logo IBT Logo
  • En
  • Sv
  • Home
  • About IBT
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
    • Sustainability Policy
  • Pipeline
    • IBP-9414
    • IBP-1016
    • IBP-1118
    • IBP-1122
    • Expanded Access Policy for Investigational Drugs
  • Healthcare Professionals
  • Investors & Media
    • Shares
    • Share Issue
    • Ownership Structure
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • Investors & Media Contact
  • Contact Us
  • Career

Press releases


Prospectus relating to IBT’s rights issue published
April 27, 2016

To access the press release, please read the following disclaimer here.

Latest press releases

2026-03-03 07:00 Infant Bacterial Therapeutics (IBT) publishes results from ”The Connection Study” in Pediatric Research
2026-02-06 07:30 Infant Bacterial Therapeutics AB (publ) Year-end-report January 1 – December 31, 2025 Regulatory
2025-12-11 18:05 Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
2025-11-25 18:41 IBT changes the IBP-9414 pathway for approval following discussions with the FDA Regulatory MAR
2025-11-20 16:42 Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance
Contact | info@ibtherapeutics.com
© Copyright Infant Bacterial Therapeutics AB 2026
Cookie Policy Privacy Policy Terms of Use